CTT PHARMACEUTICAL HOLDINGS, INC.

S-1/A amended

CTT Pharmaceutical Holdings, Inc. is advancing its strip technology, a paper-thin polymer film for rapid oral delivery of pharmaceutical agents. The technology addresses challenges with traditional formulations, such as difficulty swallowing, bitter taste, and instability, by enabling fast dissolution and precise dosing. The company highlights its proprietary heating/cooling manufacturing process and extensive patent portfolio, including coverage for nicotine, vitamins, and caffeine. CTT emphasizes partnerships for pharmaceutical product development due to high market entry costs and notes ongoing efforts to secure testing data from Health Canada for THC strips.

S-1/A amended

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is advancing its proprietary strip technology, a dissolvable oral film designed to deliver pharmaceutical agents rapidly and effectively, addressing limitations of traditional dosage forms like tablets and liquids. The technology aims to improve patient compliance by overcoming issues such as slow absorption, difficulty swallowing, and unpleasant taste. The company highlights partnerships for pharmaceutical product development, focusing on nicotine, vitamins, and other agents, while emphasizing its patented manufacturing process and intellectual property coverage across multiple regions. The filing underscores the potential for commercialization in pain management and other therapeutic areas, with a focus on rapid dissolution and ease of administration.

S-1/A amended

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on developing an orally administrable strip technology for pharmaceutical and nutraceutical delivery. The strip, a paper-thin polymer film, dissolves rapidly in saliva, addressing limitations of traditional oral medications such as slow onset, poor patient compliance, and formulation instability. The company emphasizes its patented technology, which enables precise dosing and improved bioavailability, targeting pain management and other therapeutic areas. The filing highlights the strip's potential to overcome challenges in drug delivery, including addiction risks associated with opiates and the limitations of liquid or solid dosage forms.

S-1/A amended

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is conducting an IPO involving the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners under an Equity Line of Credit Agreement (ELOC). The company, a development-stage entity focused on fast-dissolving drug delivery systems, seeks to raise up to $10 million via the ELOC for working capital and strategic purposes. The filing highlights risks related to its early-stage operations, lack of revenue, and reliance on a single product platform.

S-1 filed

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on developing fast-dissolving oral drug delivery systems using advanced thin dissolvable strips. The company is registering 6,250,000 shares of common stock for resale by RH2 Equity Partners, a selling stockholder, under a Committed Equity Financing Agreement (ELOC). While the company will not receive proceeds from the resale, it may receive up to $3 million in gross proceeds from future sales under the ELOC, intended for working capital and manufacturing expansion. The offering highlights risks related to its early-stage development, reliance on patents, and market adoption of its technology.